Figure 5.

Summary of quantitative neutralizing antibody (nAb) and multifunctional cytomegalovirus (CMV)–specific T-cell responses according to CMV prevention strategy and the seropositive-recipient (R+) control group. Data were normalized for display, with orange representing the maximum response and blue, no response. CD4 and CD8 multifunctional CMV-specific T-cell responses were log-transformed before normalization. Abbreviations: AP, antiviral prophylaxis; PET, preemptive therapy; R+, CMV seropositive control transplant patients.